NOVORAPID 30/70 FLEXP

About

Novorapid 30/70 FlexPen contains Biphasic Insulin Aspart, a pre-mixed insulin analog consisting of 30% soluble insulin aspart (rapid-acting) and 70% protamine-crystallized insulin aspart (intermediate-acting). This formulation is designed to provide both a rapid onset of action to control post-meal glucose excursions and a prolonged effect to cover basal insulin requirements. It is indicated for the treatment of diabetes mellitus in adults, adolescents, and children aged 10 years and above who require insulin to maintain adequate glycemic control. The rapid-acting component starts working quickly, typically within 10-20 minutes, while the intermediate-acting component provides coverage for several hours. This combination helps to simplify insulin regimens by addressing both prandial and basal needs with fewer daily injections. Consistent blood glucose monitoring and adherence to administration timing relative to meals are crucial for optimal therapeutic outcomes and to minimize the risk of hypoglycemia.

Uses

• Treatment of type 1 diabetes.
• Treatment of type 2 diabetes.
• To manage post-meal blood glucose spikes.
• To provide sustained basal insulin levels.

Directions For Use

Administer subcutaneously immediately before a meal (0-10 minutes). Rotate injection sites.

Benefits

• Rapid onset of action for mealtime control.
• Provides sustained basal insulin coverage.
• Reduces the number of daily injections.
• Effective for overall glycemic management.
• Helps prevent long-term diabetes complications.
• Convenient pre-mixed formulation.

Side Effects

• Hypoglycemia
• Injection site reactions (pain, redness, itching)
• Lipodystrophy
• Weight gain
• Peripheral edema
• Allergic reactions
• Pruritus
• Rash
• Urticaria
• Blurred vision (transient)
• Headache
• Nausea

Safety Measures

• Alcohol - Alcohol can lower blood sugar and increase the risk of hypoglycemia. Use with caution and monitor blood glucose.
• Pregnancy - Generally considered safe for use during pregnancy. Close monitoring of blood glucose is essential.
• Breastfeeding - Insulin is not excreted into breast milk and is safe for use while breastfeeding.
• Liver - Dose adjustments may be necessary in patients with hepatic impairment due to altered insulin metabolism.
• Kidney - Dose adjustments may be required in patients with renal impairment due to reduced insulin clearance.
• Lung - No specific contraindications or precautions related to lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.